The Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy – A Randomized Cross-Over Study
Open Access
- 10 May 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (5) , e62736
Abstract
Laboratory research and previous study suggest that aliskiren, a direct renin inhibitor, has anti-proteinuric effects. We conducted a randomized crossover study to evaluate the anti-proteinuric effect of aliskiren in patients with immunoglobulin A (IgA) nephropathy. We studied 22 patients with biopsy-proven IgA nephropathy and persistent proteinuria despite angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB). Patients were randomized to either oral aliskiren 300 mg/day or placebo for 16 weeks and then crossed over to the other treatment arm after a washout period. Proteinuria, estimated glomerular filtration rate (eGFR), blood pressure, and serum potassium were monitored. After aliskiren treatment, there was a significant reduction in proteinuria in 4 weeks (1.76±0.95 to 1.03±0.69 g:g-Cr, p2, p = 0.013) and diastolic blood pressure (72.6±12.3 to 66.2±11.2 mmHg, p<0.0001). None of the patient developed severe hyperkalemia (serum potassium ≥6.0 mmol/l) during the study period. Aliskiren has anti-proteinuric effect in patients with IgA nephropathy and persistent proteinuria despite ACE inhibitor or ARB. Further studies are needed to confirm the renal protecting effect of direct renin inhibition in chronic proteinuric kidney diseases. ClinicalTrials.gov NCT00870493Keywords
This publication has 33 references indexed in Scilit:
- Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney diseaseBMC Nephrology, 2012
- Aliskiren in Combination with Losartan Reduces Albuminuria Independent of Baseline Blood Pressure in Patients with Type 2 Diabetes and NephropathyClinical Journal of the American Society of Nephrology, 2011
- Impact of Baseline Renal Function on the Efficacy and Safety of Aliskiren Added to Losartan in Patients With Type 2 Diabetes and NephropathyDiabetes Care, 2010
- The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classificationKidney International, 2009
- The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibilityKidney International, 2009
- Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetesKidney International, 2008
- Modified Glomerular Filtration Rate Estimating Equation for Chinese Patients with Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2006
- Renin InhibitionJournal of the American Society of Nephrology, 2005
- Blood Pressure Lowering in Essential Hypertension With an Oral Renin Inhibitor, AliskirenHypertension, 2003
- Outcome of IgA nephropathy in adults graded by chronic histological lesionsAmerican Journal of Kidney Diseases, 2000